drugset

drugset / Trial / NCT06368167

A Phase II Study of SHR2554 in Patients With Relapsed or Refractory Follicular Lymphoma

NCT06368167 ↗

Phase 2 Not yet recruiting 105 enrolled Jiangsu HengRui Medicine Co., Ltd.

NaSingle-groupOpen-labelTreatment

Summary

The study is being conducted to evaluate the efficacy and safety of SHR2554 in Patients with Relapsed or Refractory Follicular Lymphoma

Timeline

Start: 2024-04
Primary completion: 2027-04
Completion: 2027-04

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	SHR2554	Small molecule	—	—

Indications